Is NAUT or PACB more undervalued in 2026?

CirclFi compares Nautilus Biotechnology, Inc. (NAUT) and Pacific Biosciences of Californ (PACB) using 13 institutional-grade valuation models. NAUT has a Quality of Company score of 4.3/10 while PACB scores 5.7/10.

Which is a better buy — NAUT or PACB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NAUT and PACB valuations compare?

NAUT at $2.74 and PACB at $1.49 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NAUT vs PACB Valuation Comparison 2026 — Intrinsic Value Analysis

NAUT

Laboratory Analytical Instruments

Nautilus Biotechnology, Inc.

Quality

4.3

out of 10

Value Trap

SAFE

Price

$2.74

Last close

Models

7/13

Active

PACB

Laboratory Analytical Instruments

Pacific Biosciences of Californ

Quality

5.7

out of 10

Value Trap

WARN

Price

$1.49

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	NAUT Fair Value	NAUT Upside	PACB Fair Value	PACB Upside
Bayesian DCF	Intrinsic	$0.61	-77.6%	$2.54	+48.4%
Earnings Power Value	Intrinsic	—	—	$1.49	-6.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.86	-68.7%	—	—
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NAUT vs PACB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NAUT vs PACB — Which Stock Is More Undervalued?

PACB scores higher with a 5.7/10 quality rating vs NAUT's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Nautilus Biotechnology, Inc. (NAUT) and Pacific Biosciences of Californ (PACB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NAUT currently trades at $2.74 with a QOC of 4.3/10, while PACB trades at $1.49 with a QOC of 5.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).